Well Done LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 9,698 shares of the medical research company’s stock, valued at approximately $1,060,000.
A number of other institutional investors have also recently made changes to their positions in EW. ETF Managers Group LLC bought a new stake in Edwards Lifesciences Corporation in the 2nd quarter valued at about $112,000. Shine Investment Advisory Services Inc. bought a new stake in Edwards Lifesciences Corporation in the 2nd quarter valued at about $126,000. Cornerstone Advisors Inc. raised its stake in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares during the period. Alexandria Capital LLC raised its stake in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares during the period. Finally, MPS Loria Financial Planners LLC bought a new stake in Edwards Lifesciences Corporation in the 2nd quarter valued at about $140,000. Institutional investors and hedge funds own 82.37% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Well Done LLC Takes $1.06 Million Position in Edwards Lifesciences Corporation (EW)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/10/30/well-done-llc-takes-1-06-million-position-in-edwards-lifesciences-corporation-ew.html.
In other news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total value of $3,816,071.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $108.54, for a total value of $2,057,918.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 158,280 shares of company stock worth $17,899,382. Corporate insiders own 2.13% of the company’s stock.
Shares of Edwards Lifesciences Corporation (EW) traded down 1.30% during mid-day trading on Monday, reaching $100.59. The company’s stock had a trading volume of 751,518 shares. The stock has a market capitalization of $21.24 billion, a P/E ratio of 30.51 and a beta of 0.62. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The company’s 50-day moving average price is $110.49 and its 200-day moving average price is $112.40.
Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. During the same period in the previous year, the firm earned $0.68 EPS. The business’s revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post $3.75 earnings per share for the current fiscal year.
EW has been the topic of a number of research reports. Stifel Nicolaus restated a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Bank of America Corporation boosted their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Jefferies Group LLC boosted their price objective on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. BidaskClub cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research report on Tuesday, July 18th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $125.17.
Edwards Lifesciences Corporation Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.